Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erdafitinib vs investigator-choice intravesical chemotherapy in high-risk NMIBC with FGFR alterations after BCG
2019-002449-39Phase 2Active
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of erdafitinib in bladder cancer (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Recurrence-free survival. Started Dec 2019; status: active.
02
Drugs
erdafitinib
03
Conditions
bladder cancer
Beyond the preview
Go deeper on 2019-002449-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002449-39.